immune-checkpoint

Documents about immune-checkpoint

• Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma#444870ClinicalTrials.gov
• Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers#1046162ClinicalTrials.gov
• Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)#208443ClinicalTrials.gov
• Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer#274674IRIS
• Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer#374506HAL (France)
• A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer#839804ClinicalTrials.gov
• Pharmacokinetic Study of Therapeutic Plasma Exchange#904769ClinicalTrials.gov
• Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment#830950ClinicalTrials.gov
• Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors.#415654NCBI PubMed Central
• Fertility and Pregnancy After Avelumab Treatment#125842ClinicalTrials.gov
• Genetic Determinants of Myocarditis Induced by Immune-checkpoint Inhibitors#226248ClinicalTrials.gov
• DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER#454023ClinicalTrials.gov
• Autoimmune Endocrine Disease Related Antibodies Before the Start of Immune Checkpoint Inhibitor Therapy#460093ClinicalTrials.gov
• Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology#677814IRIS
• Supplementary file 1_Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.docx#1038752Figshare
• Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study#338818OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Pseudohypoxia induced by iron chelator activates tumor immune response in lung cancer#194773OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Antibiotic use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database.#214053NCBI PubMed Central
• Natural polysaccharides as immune adjuvants to overcome immune checkpoint inhibitor resistance: mechanistic insights, clinical evidence, and translational challenges.#476858NCBI PubMed Central
• Ursodeoxycholic Acid Alone Is Effective and Safe to Treat Cholestatic Checkpoint Inhibitor‐Induced Liver Injury#280347HAL (France)
• Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer#268016ClinicalTrials.gov
• CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival.#353279ClinicalTrials.gov
• ICIAM Rehabilitation Program Study: A Randomized Controlled Trial#369833ClinicalTrials.gov
• Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer#411395ClinicalTrials.gov
• Guillain–Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study#676798HAL (France)
• Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma#677166HAL (France)
• Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer#907966ClinicalTrials.gov
• Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis#889893ClinicalTrials.gov
• Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma#4567Europe PMC
• Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors#325292ClinicalTrials.gov
• Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED#831664ClinicalTrials.gov
• Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors#1032986ClinicalTrials.gov
• CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target.#182548NCBI PubMed Central
• Antibiotic Timing and Survival After Immune Checkpoint Inhibitor Initiation in Patients With Cancer#314177bioRxiv / medRxiv
• Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression#881630ClinicalTrials.gov
• PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade#14277HAL (France)
• Neutrophil-to-lymphocyte ratio affects the impact of proton pump inhibitors on efficacy of immune checkpoint inhibitors in patients with non‑small-cell lung cancer#194772OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Figure 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246353Figshare
• Figure 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246354Figshare
• Figure 3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246355Figshare
• Figure 4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246356Figshare
• Figure 5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246357Figshare
• Figure 6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246358Figshare
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In#1045926ClinicalTrials.gov
• Supplementary Figure S1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246359Figshare
• Supplementary Figure S2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246360Figshare
• Supplementary Figure S3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246361Figshare
• Supplementary Figure S4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246362Figshare
• Supplementary Figure S5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246363Figshare
• Supplementary Figure S6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246364Figshare